Genmab — Februar 2021
-
JvW sagde "tidligt i andet halvår af 2021", udtalt ultimo 2020
-
Duoblo. Det er ikke ein behandling man bliver helbredt af, men en livstidsforlængelse på godt 8 mdr. i snit. Disse patienter har ikke andre muligheder, så for dem er 8 mdr. oveni godt. Behandlingen er givetvis dyr.
-
Seit Montag, dem 1. Februar 2021 ist Kesimpta
(Ofatumumab) mit folgender Indikation in der Schweiz zugelassen:• Zur Behandlung von erwachsenen Patienten mit aktiven schubförmigen Verlaufsformen der Multiplen Sklerose (MS) ; small,
but Novartis' home market -
the 'Public summary of opinion on orphan designation: Teclistamab...' via https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202331
-
God morgen.
-
Asien: Kinesisk nytår holder de fleste markeder lukket - NYhttps://www.proinvestor.com/investornyt/672053/asien-kinesisk-nytar-holder-de-fleste-markeder-lukket-ny
-
Fredagens aviser med Novo Nordisk, GN og Rockwoolhttps://www.proinvestor.com/investornyt/672049/fredagens-aviser-med-novo-nordisk-gn-og-rockwool
-
Aktier: Pensionschefer tror på fortsat fremgang - GENT
https://www.proinvestor.com/investornyt/672054/aktier-pensionschefer-tror-pa-fortsat-fremgang-gent -
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind